Clinical Trial Update: Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A [Phase 3]

View source ↗

Summary

Phase 3 trial completed to establish bioequivalence between ReFacto AF and Advate for Hemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• ADVATE (antihemophilic factor VIII)
• Refacto AF (Factor VIII, recombinant)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED